NeuroOne Medical Technologies will release Q2 2025 financial results on May 13, 2025, with a conference call discussion.
Quiver AI Summary
NeuroOne Medical Technologies Corporation will release its financial results for the fiscal second quarter ending March 31, 2025, on May 13, 2025, before the market opens. The company, focused on enhancing surgical care for neurological disorders, will conduct an investor conference call at 8:30 a.m. Eastern time on the same day to discuss its financial results and provide a corporate update, followed by a Q&A session. Participants can join the call using the provided dial-in information and access a playback until May 27, 2025. NeuroOne is developing minimally invasive solutions for EEG recording and brain stimulation for conditions including epilepsy and chronic pain, with potential applications in other areas like depression and artificial intelligence.
Potential Positives
- NeuroOne will release its financial results for the second quarter, providing transparency and updates to investors, which can enhance investor confidence.
- The scheduled investor conference call allows for direct communication between management and stakeholders, promoting engagement and accountability.
- The company’s focus on minimally invasive and hi-definition solutions for neurological disorders addresses significant medical needs, potentially increasing market relevance and impact.
- NeuroOne identifies opportunities to expand its technology applications into other health areas, indicating potential for growth and diversification.
Potential Negatives
- The press release indicates that NeuroOne is preparing to announce its financial results, which may suggest potential volatility or uncertainty regarding its fiscal performance for the second quarter of 2025.
- The absence of specific financial metrics or projections in the press release might raise concerns among investors regarding the company's performance transparency and financial health.
- NeuroOne's involvement in various complex medical technologies may imply significant R&D expenses, which could be seen as a risk if the commercialization of these technologies does not yield expected returns.
FAQ
When will NeuroOne release its financial results?
NeuroOne will release its financial results for Q2 2025 on May 13, 2025, before market open.
What time is the investor conference call scheduled?
The investor conference call is scheduled for 8:30 a.m. Eastern time on May 13, 2025.
How can I participate in the conference call?
You can participate by calling 888-506-0062 (U.S.) or 973-528-0011 (international) with access code 655933.
Will there be a replay of the conference call available?
Yes, a playback of the call will be available until May 27, 2025, at 877-481-4010 (U.S.) or 919-882-2331 (international).
What areas does NeuroOne's technology focus on?
NeuroOne develops solutions for epilepsy, Parkinson’s disease, and other neurological disorders, aiming to improve patient outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NMTC Insider Trading Activity
$NMTC insiders have traded $NMTC stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NMTC stock by insiders over the last 6 months:
- RONALD W. MCCLURG (Chief Financial Officer) purchased 200,000 shares for an estimated $100,000
- DAVID A ROSA (CEO and President) purchased 100,000 shares for an estimated $50,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NMTC Hedge Fund Activity
We have seen 7 institutional investors add shares of $NMTC stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 798,762 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $659,697
- PERKINS CAPITAL MANAGEMENT INC removed 150,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $123,885
- CITADEL ADVISORS LLC added 81,802 shares (+inf%) to their portfolio in Q4 2024, for an estimated $67,560
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. added 81,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $68,866
- MAI CAPITAL MANAGEMENT added 50,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $41,295
- JANE STREET GROUP, LLC added 39,951 shares (+inf%) to their portfolio in Q4 2024, for an estimated $32,995
- AWM INVESTMENT COMPANY, INC. removed 33,333 shares (-2.8%) from their portfolio in Q4 2024, for an estimated $27,529
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025.
Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company’s second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:
Second Quarter 2025 Earnings Conference Call
Date: Tuesday, May 13, 2025
Time: 8:30 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 655933
Webcast:
2Q25 Webcast Link
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through Tuesday, May 27, 2025. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 52404. A webcast replay will also be available using the webcast link above through May 27, 2025.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com .
IR Contact
MZ Group – MZ North America
[email protected]
